A phase 1, open‐label, 2‐sequence, 2‐treatment, 2‐period, crossover study assessing the absolute oral bioavailability of Lorlatinib in healthy subjects
Latest Information Update: 08 Mar 2022
At a glance
- Drugs Lorlatinib (Primary) ; Lorlatinib (Primary)
- Indications Cancer; Neuroblastoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- 21 Apr 2021 New trial record
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics